Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LSM2 pseudogene 1 (LSM2P1) is a pseudogene related to LSM2, which encodes a member of the LSm family of RNA-binding proteins involved in pre-mRNA splicing and mRNA decay[1][4]. Pseudogenes like LSM2P1 generally do not produce functional protein products and are considered non-functional remnants of genes; however, some pseudogenes can participate in genetic regulation or be expressed as non-coding RNAs, though no such function is validated for LSM2P1[5]. There are no reported roles for LSM2P1 as a therapeutic target, and its entry as a molecular target is incorrect, as it does not encode a functional protein or receptor[1][4][5]. Key clarification: - *LSM2* (not the pseudogene LSM2P1) is the protein-coding homolog, part of RNA metabolism and splicing complexes, and is being actively studied in the context of cancer and RNA processing[1][2][4]. The information and disease linkage in literature generally pertain to LSM2, not to its pseudogene variants. - *LSM2P1* is just a genomic sequence in the human genome, not a functional target, receptor, or enzyme. This entry should not be considered a true molecular target for therapeutic or biomarker development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LSM2 pseudogene 1 (LSM2P1).